News & Updates

In the treatment of children with obstructive sleep apnoea syndrome (OSAS), use of intranasal corticosteroids falls short of producing substantial changes in symptoms as well as in polysomnographic and neurobehavioural parameters at 3 and 12 months, a study has found.

The KRAS^G12C inhibitor adagrasib shows durable clinical benefit, without new safety signals, in pretreated patients with advanced non–small cell lung cancer (NSCLC) harbouring a KRAS^G12C mutation in the KRYSTAL-1 trial.

Use of 2.5-mg tissue plasminogen activator (tPA) and 5-mg deoxyribonuclease (DNase) therapy as a starting intrapleural dose, with up-titration if needed, appears effective in patients with pleural infection, suggests a study, noting that this treatment warrants further research.

The 2-year wait is over.

In healthcare workers, prophylactic therapy with doxycycline plus zinc seems to reduce the risk of contracting SARS-CoV-2 infection, according to a study.

The management of multidrug-resistant (MDR) infections in children is complex, with limited studies and a relative lack of approved new antibiotics with paediatric indications.

At a recent Meet-the-Expert session, Dr Louis Grandjean, Consultant in Paediatric Infectious Diseases at Great Ormond Street Hospital and Associate Professor at University College, London, UK, addressed the growing threat of MDR infections in children and discussed treatment strategies and options for management. He focused on ceftazidime-avibactam (CAZ-AVI, Zavicefta^®), whose approval in Singapore was recently expanded to include paediatric patients aged 3 months and older.

Adj Asst Prof Natalie Tan, Senior Consultant at KK Women’s and Children’s Hospital, Singapore, chaired this webinar, which was organized by Pfizer under the auspices of the Singapore Paediatric Society and KK Women’s and Children’s Hospital.